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ABSTRACT  
During the past few years, graphene has outstandingly emerged as a key nanomaterial for boosting 
the performance of commercial, industrial and scientific related technologies. The popularity of 
this novel nanomaterial in biomedical engineering is due to its excellent biological, electronic, 
optical and thermal properties that, as a whole, surpasses the features of commonly used 
biomaterials and consequently open a wide range of applications so far within the reach of science 
fiction. In this minireview, the potential of graphene and its based materials in the expanding 
biomedical field is highlighted with focus on groundbreaking diagnostic, monitoring and 
therapeutic strategies. Some of the major challenges related to the synthesis and safety of 
graphene-based materials are also briefly discussed because of their critical importance in bringing 
this class of carbon materials closer to the clinic. 
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INTRODUCTION 
Since it was successfully isolated for the first time in 20041, graphene has proved to be a 
frontrunner nanomaterial for a wide range of biomedical engineering applications2 by 
narrowing the gap among biology, electronics and nanoscience towards the development 
of more efficient diagnostic3 and therapeutic4 strategies. The vertiginous uprising of 
graphene in the biomedical field is intrinsically related to its set of amazing features, 
combining enhanced electrical, thermal, optical and mechanical properties with promising 
levels of biocompatibility. Briefly, graphene is a 2D flat monolayer of sp2 hybridized 
carbon atoms arranged in a honeycomb fashion that can work as a basic building block for 
other carbon related materials: graphene can be wrapped up into fullerenes (0D), rolled into 
carbon nanotubes (1D) or piled up into 3D graphite crystals5. From a functional point of 
view, the 2D arrangement guarantees a notably high specific surface area that can be used 
to establish suitable cell-material interactions6 and to provide multiple attachment spots for 
biomolecules7. The remarkable electronic and optical properties of graphene are deeply 
linked with its singular electronic band which, by combining both metallic and 
semiconducting characteristics, allows the π electrons to behave like ultrarelativistic 
particles able to move with a speed close to the speed of light. Indeed, this nanomaterial is 
a bioactive and transparent zero-gap semiconductor capable of significantly upgrading the 
selectivity and sensitivity of both electrochemical, field-effect transistor (FET) and optical 
biosensors8, 9 in the road to more efficient enzymatic biosensing, DNA sensing, and 
immunosensing. For example, Xu et al.10 have successfully patterned six parallel 
ultrasensitive FETs onto a graphene single crystal domain in order to perform reliable and 
reproducible multiplex analysis of DNA. Relatively to 1D carbon nanomaterials, the 
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advantages brought by graphene included not only an optimal performance by measuring 
the kinetics of DNA hybridization and minutely distinguishing single-base mutations in 
real time, but also the implementation of a more cost- and time-efficient fabrication 
technique and a simpler functionalization process. In a similar way, the fabrication of 
nanopores in a graphene sheet proved to be an auspicious strategy to unveil the exact DNA 
sequences that encode the genetic mechanisms of tumors and hereditary diseases. Actually, 
according to many experimental and theoretical studies11, 12, due to the capability of 
graphene nanopores to detect minimal fluctuations in the ionic flow that moves within, it 
is possible to precisely associate the passage of each nucleobase through the nanopore with 
a particular blockage and magnitude variation of the induced ionic electrical current. 
Concerning the efficiency of this process, both the customization of the graphene nanopores 
with biological markers like layers of DNA-origami13 and the combination of graphene 
with other 2D nanomaterials such as molybdenum disulfide14 are suitable options to reduce 
the velocity of the DNA passage through the nanopore and therefore to boost a more 
accurate sequencing process. Additionally, biomedical researchers are currently exploring 
the capability of graphene to act as an exceptional reinforcing filler for biomedical 
platforms due to the mechanical integrity and intrinsic lightness of its 2D honeycomb 
structure, where each carbon atom is covalently bonded with its three nearest carbon 
neighbors4. As the graphene-based biocomposites are easily compatible with a wide range 
of nanofabrication techniques, it is often possible to shape their morphology to match 
different cellular microenvironments such as fibrous15 and porous16 structures. In these 
lines, the presence of graphene was a critical factor to enhance the performance of a 
polyacrylamide hydrogel proposed as a 3D neural tissue engineering (TE) scaffold as 
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neurons were only able to generate neuronal networks capable of supporting synaptic 
activity when cultured in those hybrid hydrogels containing graphene17. 
Complementary to graphene, graphene oxide (GO) presents a highly reactive surface, with 
hydrophobic sp2 carbon regions intercalated by sp3 regions where the carbons are linked 
with oxygen functional groups (carboxyl, epoxy and hydroxyl) that guarantee the presence 
of hydrophilic zones able to promote good water dispensability, a near infrared (NIR) to 
visible fluorescence and also covalent and/or non-covalent attachment points for 
biomolecules, metals and polymers18. This singular mix of features is receiving increased 
attention from biomedical engineers, who look to GO as the central building block for 
versatile strategies capable of combining imaging, sensing and therapy19, 20. For instance, 
GO can be simultaneously used for drug delivery and live cellular imaging by diffusing its 
oxygen moieties via a mild thermal annealing procedure able to maintain their availability 
to be conjugated with cancer drugs while inducing blue fluorescence21. In other example of 
cancer nanotheranostics22, GO was successfully combined with Bi2Se3 nanoparticles and 
polyvinylpyrrolidone with the purpose of synthetizing a multifaceted nanocomposite able 
to match an excellent performance as X-ray computer tomography and photoacoustic 
contrast agent for tumor visualization in vivo with an enhanced capability to induce a 
permanent removal of cancer cells via photothermal therapy (Figure 1). Moreover, 
depending on the biomedical application, the GO functionality can be successfully tuned 
by adapting the size of the nanosheets23, 24 or by partially removing its oxygen functional 
groups25, 26 via either chemical or thermal methodologies, leading to reduced graphene 
oxide (rGO), which displays closer properties to those of pristine graphene. However, rGO 
is conceptually a different nanomaterial relatively to graphene since both the removal of 
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oxygen functional groups and the restoration of the π-π conjugation that occur during the 
reduction process are not able to induce a uniform sp3 – sp2 hybridization throughout all 
the extension of the carbon network27. In this way, by controlling the degree of reduction, 
it is possible to modulate the quantity of topological defects and residual oxygen moieties 
that are capable of influencing the biological, chemical, electrical, mechanical, optical and 
thermal properties of the final nanomaterial28-30. For example, Chen et al.31 have studied 
the capacity of three different chitosan derivatives to work simultaneously as reducing and 
stabilizing agents for GO with the final purpose of selecting the composite with less oxygen 
content and therefore with a more integrated conjugated carbon network for further drug 
delivery testing. Results showed that the presence of such composite into the final hydrogel 
beads was crucial to ensure an efficient π-π stacking with the drug and subsequently 
guaranteed a better encapsulation capacity and an enhanced drug release profile 
comparatively to its oxidized counterpart. 
In this mini-review, the impact of graphene-based materials (GBM) in biomedical 
engineering is highlighted by discussing their potential inclusion in advanced diagnostic, 
monitoring and therapeutic approaches. Also, the viability of this set of carbon materials in 
the healthcare field is presented by focusing in essential issues such as the development of 
new synthesis methodologies and the necessity of conclusive studies regarding their short- 
and long-term toxicity. 
GBM in diagnostics and healthcare monitoring 
In order to overcome the limited access to health diagnostic and monitoring services, which 
are mostly located on hospital and clinical settings, there is a growing need to develop 
portable and therefore cost-effective biomedical devices capable of comfortably reaching 
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patients living in remote areas. Additionally, such platforms should ideally be real-time 
personalized tools capable of guaranteeing an accurate recognition of relevant 
physiological changes by the patient, avoiding the need for a continuously data analysis by 
highly skilled healthcare professionals. Possible strategies for reaching this goal and 
subsequently respond to the guidelines of the World Health Organization for ASSURED 
devices (Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment free 
and Deliverable to end-users)32 include diagnostic and routine health tests performed with 
upgraded smartphones33, health monitoring via either non-invasive flexible biosensors34 or 
implantable biophotonic devices35, ingestible electronics36 as diagnostic tools and 
biomedical tattoos37 able to early detect diseases such as cancer. Some of these 
revolutionary approaches deeply rely on the multifunctional behaviour of carbon-based 
nanomaterials38, 39, especially graphene, due to their singular electrical and optical 
properties and their ability to be incorporated into advanced composites.  
Indeed, the placement of graphene as a central player for developing the new generation of 
diagnosing and monitoring platforms is being strongly sustained by interdisciplinary inputs 
from biology, chemistry, electronics and physics, facilitating the upgrading of such devices. 
One remarkable example is the progress in the conception and fabrication of biosensors, 
where GBM can efficaciously integrate a wide range of ex situ bioanalytical systems2, 9 that 
allow an accurate identification of targeted molecules, proteins and cells collected from the 
patient. In some strategies, these target entities establish a direct electron transfer with 
graphene, which offers several advantages as electrode material8, 40 by showing a large 
specific surface area, a fast electron-transfer kinetics and a notable ability to catalyse the 
redox reactions that lead respectively to an enhanced sensitivity, a boosted response time 
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and the detection of biomolecules at low electrochemical potentials. The usefulness of 
graphene-based electrodes as early diagnostic tools for some common chronic diseases 
such as cancer41, diabetes42 and HIV43 was recently reported with very promising results. 
In fact, graphene enabled not only excellent functionalization routes to enhance the 
selectivity and sensitivity of the biosensors for both small molecules (e.g. glucose) and 
biomarkers (e.g. for cancer and HIV), but simultaneously broadened the range of available 
cost-effective design and fabrication techniques concerning electrochemical sensing 
platforms. Moreover, graphene-based electrodes can also be adapted to integrate real time 
monitoring modalities. For example, Lee et al.44 have developed a wearable graphene-
hybrid interface capable of detecting glucose above a critical concentration by analysing 
the sweat on the skin of the patient and, if necessary, counterbalancing the excessive 
glucose levels with a controlled drug delivery system provided by bioresorbable 
temperature responsive microneedles (Figure 2). Although multifunctional platforms able 
to both sense abnormal levels of glucose and induce a negative feedback response are 
currently presented as an ideal approach for controlling diabetes, a more near-future 
scenario will include gadgets such as smartphones equipped with screen-printed electrodes 
(SPE)45 capable of recoil physiological data and aware the patient through user-friendly 
applications. A promising route for fabricating SPE was reported recently46, showing a two-
step strategy where, firstly, GO was first combined with a glucose sensitive substance (3-
amino phenylboronic acid) and then reduced with the purpose of enhancing the 
conductivity of the composite. At the end, the rGO composite electrode was able to 
successfully bind glucose and consequently trigger the smartphone-based cyclic 
voltammetry detection system, which was displayed on the screen in real-time. Other 
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groundbreaking sensing strategies are presently focused on biomedical devices able to 
meticulously detect cancer cells47, 48. One example was reported by Wang et al.49, who 
fabricated a 3D graphene biointerface capable of using its irregular and conductive surface 
to enhance the formation of filopodia from the cells due to the established multidimensional 
cell-material interactions. Then, by combining these topographical features with the 
potential of graphene to be used as an electrode material, it was possible to upgrade the 
recognition of the electrical impedance signals coming from cancer cells (relative to the 
cell capture and sensing efficiencies) with respect to standard 2D gold interfaces.  
The impact of graphene is also noticeable in the production of advanced FET biosensors50 
since its presence between the source and the drain contacts of the sensing platform offers 
advantages comparatively to other materials (e.g. silicon) including high transconductance, 
stable performance and low working voltage. Also, these graphene-based FET biosensors 
present highly tuneable chemical51 and morphological52 features that can robustiously 
support a wide range of critical healthcare challenges including the detection of bacteria in 
contaminated water53 and the prevention of heart failure54. On the other hand, the optical 
behaviour of GBM is also being addressed as a promising characteristic for efficient 
sensing and imaging strategies. For instance, changes in the optical features provoked by 
the adsorption of hemoglobin onto a GO coated fibre grating can easily identify abnormal 
concentrations of this molecule in the blood for anemia diagnostics55. Similarly, graphene 
is dramatically shifting paradigms in cell imaging by allowing exhaustive real-time 
monitoring of cellular morphology and physiology either via high resolution optical 
platforms able to detect even the variations in the refractive index of subcellular 
components56 or via quantum dots fluorescence57, 58. 
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Adding to its excellent electrical and optical properties, graphene presents a very interesting 
set of biological and mechanical properties that allow a solid bridging between ex situ 
sensing/monitoring modalities and in situ sensing implants2, 59, 60. In fact, the enhanced 
levels of biocompatibility, flexibility and resistance of graphene-based devices enable a 
continuous, efficient and long-term signal detection and processing despite the stresses 
intrinsic to biological environments. Taking this into account, biomedical engineers are 
currently focusing efforts to expand the functionality of common healthcare accessories 
such as contact lenses61 by upgrading them with flexible and transparent electronics (e.g. 
biosensors and wireless antennas) capable of maintaining their performance independently 
of the continuous eye blinking. Some advancements boosted by graphene include the 
recording of electroretinograms62, diabetes and glaucoma diagnostics63 and the 
enhancement of eye protection64 against dehydration and electromagnetic waves. Likewise, 
other emerging new class of wearable electronics embraces multifunctional graphene 
electronic tattoos. A pioneer example was reported recently by Ameri et al.65, who have 
used a “wet transfer, dry patterning” methodology to fabricate a device capable of 
efficiently perform common physiological measurements like electrocardiograms, 
electromyograms and electroencephalograms (Figure 3). Also, in this case, graphene was 
indispensable to guarantee a temporal attachment to the skin via van der Waals forces, a 
mechanical integrity able to resist skin deformations and an optical transmittance adequate 
to make the electronic tattoo unnoticeable. 
GBM in therapeutic strategies 
GBM are currently one of the most significant opportunities of modern science to unlock 
sustainable solutions for some of the major challenges concerning cancer therapeutics and 
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regenerative medicine4, 66. This expectation comes from the possibility of rearranging 
specific sets of graphene related properties depending of the implemented strategy. For 
instance, the modulation of solubility, photosensitivity and load capacity can enhance the 
efficiency of cancer treatment modalities such as drug delivery67, 68 and phototherapy69, 70. 
Moreover, the chemical, electrical and mechanical tunability of GBM can enhance the 
features of advanced TE scaffolds71, leading to a meticulous recreation of specific cellular 
microenvironments and consequently to a successful reinforcement or replacement of 
natural regeneration processes. Thus, graphene seems to perfectly fit into the concept of 
personalized medicine72, 73, which states that, ideally, a therapeutic agent should be tailored 
to match the specific requirements of the patient and then delivered/implanted with 
precision in the target area without toxic effects. 
In fact, although the heterogeneity of cancer74 is presently compromising the fulfilment of 
personalized medicine, new insights brought by nanotechnology and nanomedicine during 
the past few years have allowed the growing of nanotheranostics38, 75 as a near-future 
promising alternative to fight this devastating disease. This approach requires the 
development of multifunctional nanomedical systems able to detect and kill cancer cells 
while the efficiency of their performance is monitored. Biomedical engineers are placing 
GBM, specifically GO20, 66, as a cornerstone to build nanotheranostic strategies encouraged 
by its improved levels of biocompatibility and stability relatively to other common 
materials like metals and polymers. Additionally, its functionality enables an easy surface 
modification with anchored ligands (e.g. drugs, peptides and proteins) able to selectively 
bind to receptors overexpressed by tumours or specific cell types such as endothelial cells, 
leading to successful active targeting approaches that guarantee a localized deliver of 
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therapeutic agents (chemotherapy76 and gene therapy77) or phototherapy (e.g. 
photothermal78 and photodynamic79 therapies). For delivery purposes, GO presents a high 
surface area, aspect ratio and cell internationalization ability that fulfil important 
requirements for an excellent nanocarrier platform. Indeed, in a combinatorial strategy 
suggested by Li et al.80, GO was covalently linked to polyethylenimine with the purpose of 
anchoring two materials (folate and heparin) able to specifically recognize breast cancer 
cells. The composite was also loaded with doxorubicin, a well-known chemotherapy 
medication, via π-π and hydrophobic interactions. Then, the final compound was 
administered in vivo together with an inhibitor of the metastatic process, producing a 
synergetic effect that suppressed both the tumour growth and the pulmonary metastasis. In 
a complementary approach81, the potential of GO as a photosensitive material was explored 
in the shape of a nanocomposite capable of effectively killing solid tumours by mediating 
both photothermal and photodynamic therapies while providing in vivo multi-colour 
fluorescence imaging. Other promising modalities include the combination of the 
properties of GO/rGO with magnetic nanoparticles towards the development of advanced 
nanotheranostic systems suitable to perform magnetic resonance imaging82 and/or conduct 
magnetic targeting83. 
Other offshoot of personalized medicine involves the modulation of stem cell biology in 
the direction of progressive therapies able to replace the current regenerative medicine 
approaches (e.g. allografts) by reprogramming patient’s mature cells into an immature state 
– induced pluripotent stem cells (iPSCs) – and control their further differentiation into a 
selected cell type84. In this way, it would be possible to suppress significant limitations like 
donor availability, immune rejection and ethical issues since the patient will be both the 
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source and the receiver of the cells85. However, before reaching this ideal scenario, it is 
mandatory to deepen our knowledge on the maintenance of the differentiated phenotype of 
the cells as well as on their expansion, differentiation, transplantation and protection during 
and after the treatment. Thus, one of the hottest topics in the field of regenerative medicine 
is the in vitro recreation of cell niches skilled to provide cell-material interactions capable 
of accurately simulating the effects of specific extracellular matrices on stem cell 
behaviour. This will necessarily lead to a better understanding of the phenomena that 
modulate differentiation patterns of these cells84, 86, 87. The role of GBM in the development 
of these TE scaffolds is becoming increasingly prominent,2, 66, 71 mostly due to their 
capacity to facilitate the customization of the bulk properties, shape and functionality of 
composites applied for mimicking different cellular microenvironments such as bone, 
heart, nerve and skin. For instance, regarding bone regeneration, graphene, GO and rGO 
have been used as osteoinductive agents88 due to their ability to promote osteogenic 
differentiation of stem cells via different mechanisms. One example was recently proposed 
by Wu et al.89, who reported that the presence of graphene into a polymer film was able to 
enhance alkaline phosphatase activity, the formation of a mineralized matrix and the 
activation of a genetic signalling pathway, responsible for inducing the efficient osteogenic 
differentiation of rat bone marrow-derived mesenchymal stem cells (MSCs). 
Complementary to the dynamics of molecular circuits, graphene composites provide an 
excellent opportunity to fabricate biocompatible 3D microenvironments (e.g. porous 
networks90, 91 or electrospun fibres92) with features that also enhance both in vitro and in 
vivo osteogenic differentiation of stem cells. Some of them include surface chemistry able 
to potentiate mineralization (e.g. hydroxyapatite formation) and improve wettability, 
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interconnected porous systems capable of optimizing cell proliferation/migration across the 
scaffold, suitable biodegradation profiles and reinforced mechanical properties, among 
others.  
Alternatively, the impact of graphene can be extended to cardiac differentiation pathways. 
For example, the simple inclusion of a graphene dispersion in the mouse embryoid bodies 
(EBs) structure induced an augmentation of their electrical conductivity and Young 
modulus, leading consequently to a viable cardiac differentiation process that could be 
successfully enhanced via electrical stimulation (ES) (Figure 4)93. Another group94 has 
recently reported that graphene substrates can be used as electrically active platforms able 
to efficiently promote the differentiation of human iPSCs into cardiomyocytes and then 
improve their maturation into functional cardiac cells. Analogous to its impact in directing 
cardiac differentiation, GBM are being combined with other biomaterials for treating 
cardiovascular diseases by acting as anticoagulants95, inflammatory modulators96 and 
conductive scaffolds97-99 with electromechanical properties that encourage the seeded 
cardiomyocytes to match the behaviour of the native cardiac tissue. Additionally, such 
scaffolds can usually respond to external ES, leading to an accurate regulation of important 
features such as cell alignment and maturation. In other applications, graphene-based 
scaffolds are combined with ES in order to improve the proliferation and differentiation of 
stem cells into neural lineages100, 101. As a matter of fact, Aznar-Cervantes et al.102 have 
reported that the application of electrical stimulation onto a silk fibroin electrospun scaffold 
coated with rGO induced excellent levels of differentiation of PC-12 cells into neural 
phenotypes even without the presence of more traditionally pursued biochemical cues (e.g. 
neural growth factors). The need for growth factors to provoke differentiation was also 
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suppressed by applying ES into an inkjet-printed graphene interdigitated electrode, leading 
to an efficient transdifferentiation of MSCs into Schwann cells103. Strategies involving ES 
can also establish a preferential differentiation pathway, for example, a conductive 3D 
rolled GO foam was able to conduct electrical currents that favoured the differentiation of 
human neural stem cells into neurons rather than glia104.  
A further advantage brought by the inclusion of GBM in TE applications is their ability to 
kill bacteria via complex mechanisms such as oxidative stress and removal of phospholipids 
from the bacteria membrane105, 106. Although these mechanisms are not yet fully understood 
since they depend on the particular characteristics of both the nanosheets used (e.g. size, 
hydrophilicity) and the targeted microbial entity, their positive effects are already being 
explored in TE strategies, especially in skin regeneration107, 108. Additional benefits of 
graphene-based scaffolds in wound healing approaches include not only an extraordinary 
capacity to enhance stem cell responses both in vitro and in vivo but also degradability and 
mechanical features that match the ideal period for a subcutaneous implant (4 weeks),109 as 
well as the successful promotion of collagen deposition and angiogenesis110. 
 
Challenges and perspectives 
Although their impact is real and unmistakable, especially regarding the production of the 
next-generation of biomedical platforms, GBM still hold the status of dream materials for 
biomedical engineers since their full potential has not been either discovered or achieved 
yet. In fact, the feasibility of this class of nanomaterials in the healthcare system is not only 
related to the understanding/modulation of their properties, but also to the development of 
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new synthesis methodologies and manipulation regulations and the necessity of conclusive 
studies regarding short- and long-term toxicity.  
Nowadays, one major issue, common to the other fields where the graphene influence is 
growing, is the lack of a production methodology able to simultaneously guarantee quality, 
scalability and cost effectiveness2, 40. Indeed, neither the bottom-up synthesis strategies 
such as chemical vapor deposition nor the top-down approaches like the mechanical 
exfoliation of graphite and the modified Hummer’s methods are currently capable of 
producing high-quality GBM without costly and complex manufacturing processes, low 
yield and toxic reagents. Therefore, the development of scalable and sustainable 
methodologies based on green chemistry principles66, 111, 112 can be considered a major 
milestone to place graphene-based biomedical devices as strong candidates for real world 
applications and commercialization. In this context, a promising strategy was recently 
reported by González et al.113, who have successfully developed a mechanochemical 
treatment with carbohydrates to exfoliate graphite and subsequently generate graphene in 
an environmentally friendly approach. Another imperative progress before pondering the 
medical use of such devices must be done by regulatory authorities, who should narrow the 
large spectrum of experimental conditions around a defined safety level that could lead, 
consequently, to standardized characterization, nomenclature and results concerning 
GBM114.  
Even though the classification of GBM according to chemical (e.g. C/O ratio) and 
morphological (e.g. average lateral size, number of graphene layers) criteria must be 
extended to non-invasive diagnostic and monitoring systems to avoid dangerous long-time 
exposures of cells and/or tissues, this issue becomes even more relevant for engineering 
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implantable platforms with complete in vitro and in vivo toxicological profiles, including 
the maximum concentration and the mechanisms of delivery/degradation/elimination of the 
nanomaterials from the body2, 6, 7, 115. In fact, the evaluation of the risk-benefit balance is 
very complex and must be specific for each application due to the enormous differences 
that GBM can present in their atomic composition. For example, a recent study evaluated 
the effects of GO, chemical rGO and thermal rGO in human lung cells116, showing that 
although the higher oxygen content of GO enabled more affinity with the cell membrane, 
the smaller lateral dimensions and sharp edges of the thermal rGO were able to boost the 
cellular uptake and therefore lead to more severe consequences regarding cellular viability, 
oxidative stress, genotoxicity and cell death. Similar results were obtained by Contreras-
Torres et al.117, who reported that myocardial cells were able to efficiently internalize the 
smaller low-rGO (37% content of oxygen) sheets relatively to the original GO (54% of 
oxygen), leading to a more acute generation of oxidative stress and consequently to a 
significant lower half maximal inhibitory concentration (129.4 ± 1.2 μg mL-1 and 652.1 ± 
1.2 μg mL-1, respectively).  
Opposing to these properties, there is a small number of studies concerning the effects of 
the number of layers in the toxicity potential of GBM, notwithstanding the relevance of this 
parameter to correctly distinguish their different categories – for example graphene (i.e. 
until 10 layers of graphene) from ultrafine graphite (i.e. between 10 graphene sheets and 
100 nm of thickness)114 - and to determine other characteristics such as absorptive capacity, 
bending stiffness and specific surface area115. However, in a noticeable exception, Cho et 
al.118 have analysed the dose and size dependence toxicity in vitro and in vivo of GO 
samples with different number of layers, revealing interesting results. Specifically, the 
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binding and phagocytic uptake processes that were activated by the single-layered GO 
proved to be more influential in inducing cell damage and inflammatory responses than the 
necrotic and apoptotic mechanisms triggered by the multi-layered GO. Additionally, the 
tests in vivo showed that, independently of the number of layers, the intravenous injection 
of GO provoked inflammation in both lungs and kidneys, being the more severe results 
reported for the multi-layered GO due to its higher volume and thickness.  
Based on this, one priority of biomedical engineers should be the development of a standard 
characterization methodology for the reported GBM, which should include normative 
experimental conditions for common characterization techniques such as X-ray 
photoelectron spectroscopy (for chemical analysis) and transmission electron microscopy 
(for morphological analysis). In fact, the collection and organization of this data together 
with the parameters regarding both short- and long-term in vitro and in vivo toxicity should 
allow the construction of predictive models capable of forecasting and interpreting the 
molecular mechanisms affected by the interactions between GBM and the different 
organizational levels of livings systems (i.e. organelles, cells, tissues and organs)119-121 with 
the final purpose of consistently enhancing the biological response of the new graphene-
based biomedical platforms. For instance, in an influential theoretical study122, it was 
suggested that, after cellular uptake, the hydrophobic character and the flatness of the 
graphene nanosheets leaded to a disruption in the protein-protein hydrophobic interactions 
and consequently to functional deficiencies at the metabolic level that could result in cell 
death. This report combined with other theoretical models have reinforced the paradigm of 
functionalizing GBM with suitable biomaterials/biomolecules in order to enhance their 
biocompatibility by preventing the triggering of undesirable processes such as oxidative 
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stress, cell membrane damage and mutations capable of compromising cell survival and 
proliferation. In fact, for the immediate future, this topic should be an integral part of 
graphene research since traditional coating strategies such as PEGylation123 have presented 
unsuccessful results on improving the pharmacokinetic behaviour of GBM124-126.  
In summary, despite the innovative and extensive results provided by GBM in biomedical 
applications, including revolutionary diagnosis, monitoring and therapeutic approaches, 
there is still a long road ahead until some important concerns related to production 
processes and biological interactions including toxicity are irrefutably solved. However, it 
is quite possible that this road will be covered more quickly than expected based on the 
vertiginously rapid growth of the field and the enthusiasm of the scientific community, 
which are helping to overcome the mentioned challenges, leading to real and decisive 
breakthroughs in a near future. 
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